SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage company with a market capitalization of $210 million and a strong liquidity position as indicated by InvestingPro data, has reached its enrollment goal for a key Phase 2b clinical trial, the company announced today. The study, named REZOLVE-AD, is investigating the efficacy of rezpegaldesleukin in treating moderate-to-severe atopic dermatitis, a chronic skin condition.
Rezpegaldesleukin, a potential first-in-class interleukin-2 receptor agonist, is designed to activate regulatory T cells, which play a role in controlling immune responses. Prior clinical trials have indicated that the drug can safely and effectively increase these cells and improve disease outcomes in patients.
The REZOLVE-AD trial has enrolled 396 patients who have not previously been treated with biologic or JAK inhibitor therapies. Participants are distributed across various dosing regimens and will undergo a 16-week induction treatment period, after which they may continue to a maintenance phase based on their response. According to InvestingPro analysis, while Nektar maintains more cash than debt on its balance sheet, the company is rapidly burning through its cash reserves, highlighting the importance of this trial's success.
The primary measure of the trial's success will be the mean improvement in patients' Eczema Area and Severity Index (EASI) scores at the end of the induction period. Other key endpoints include the proportion of patients achieving significant improvements in their condition as defined by several clinical scales.
Patients were recruited globally, with a significant portion from Europe, followed by participants from the United States, Canada, and Australia. The trial's design takes into account the severity of the disease and geographic location.
This study's progress is particularly relevant given that less than 10% of the estimated 30 million atopic dermatitis patients in the U.S. and Europe who are eligible for biologic treatments currently receive them. Nektar's CEO, Howard W. Robin, expressed optimism that rezpegaldesleukin's novel mechanism could help address this treatment gap.
Topline data from the REZOLVE-AD study's induction phase is expected in the second quarter of 2025. The drug is also being evaluated in a separate Phase 2b trial for alopecia areata, an autoimmune disorder that causes hair loss.
Nektar Therapeutics, the clinical-stage company behind rezpegaldesleukin, specializes in developing treatments that target immunological dysfunction in autoimmune and chronic inflammatory diseases. The information reported here is based on a press release statement.
In other recent news, Nektar Therapeutics has been making significant strides in its operations and clinical studies. The company recently finalized the sale of its manufacturing facility in Huntsville, Alabama, to an affiliate of Ampersand Capital Partners (WA:CPAP), a move that aligns with the company's strategic initiatives to streamline operations. The sale has provided the company with over $300 million in pro forma cash, expected to fund operations into mid-2026.
Nektar's advanced candidate, REZPEG, currently in Phase IIb trials for atopic dermatitis (AD) and alopecia areata (AA), is showing promise. B.Riley initiated coverage on Nektar with a Buy rating, suggesting that REZPEG could disrupt the current AD treatment market.
In terms of financials, Nektar ended its third quarter with a strong cash position of $249 million, and anticipates a year-end increase in cash and investments to about $265 million. Full-year revenue is expected to be between $90 million and $95 million. These recent developments highlight Nektar Therapeutics' commitment to advancing its immuno-oncology pipeline and its potential to impact millions of patients worldwide. Piper Sandler, a leading investment bank, identified Nektar Therapeutics as one of the companies with key Phase 2b readouts expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.